- Home
- HCI vs AUPH Comparison
HCI vs AUPH Comparison
Compare HCI & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCI
- AUPH
- Stock Information
- Founded
- HCI 2006
- AUPH 1993
- Country
- HCI United States
- AUPH Canada
- Employees
- HCI N/A
- AUPH N/A
- Industry
- HCI Property-Casualty Insurers
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- HCI Finance
- AUPH Health Care
- Exchange
- HCI Nasdaq
- AUPH Nasdaq
- Market Cap
- HCI 1.2B
- AUPH 1.3B
- IPO Year
- HCI N/A
- AUPH 1999
- Fundamental
- Price
- HCI $114.47
- AUPH $8.77
- Analyst Decision
- HCI Buy
- AUPH Strong Buy
- Analyst Count
- HCI 5
- AUPH 3
- Target Price
- HCI $140.00
- AUPH $10.33
- AVG Volume (30 Days)
- HCI 112.1K
- AUPH 1.3M
- Earning Date
- HCI 11-07-2024
- AUPH 02-13-2025
- Dividend Yield
- HCI 1.40%
- AUPH N/A
- EPS Growth
- HCI 163.93
- AUPH N/A
- EPS
- HCI 11.94
- AUPH N/A
- Revenue
- HCI $750,846,000.00
- AUPH $220,361,000.00
- Revenue This Year
- HCI N/A
- AUPH $36.97
- Revenue Next Year
- HCI $14.52
- AUPH $16.43
- P/E Ratio
- HCI $9.58
- AUPH N/A
- Revenue Growth
- HCI 48.73
- AUPH 38.72
- 52 Week Low
- HCI $81.35
- AUPH $4.71
- 52 Week High
- HCI $126.50
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- HCI 49.20
- AUPH 45.91
- Support Level
- HCI $112.81
- AUPH $8.89
- Resistance Level
- HCI $119.73
- AUPH $9.31
- Average True Range (ATR)
- HCI 4.23
- AUPH 0.34
- MACD
- HCI 0.12
- AUPH -0.11
- Stochastic Oscillator
- HCI 56.83
- AUPH 1.43
About HCI HCI Group Inc.
HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are HCPCI insurance operations, TypTap Group, Real estate operations, and Corporate and other. It derives key revenue from the HCPCI Insurance operation segment.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.